Cue Biopharma (CUE) Cash & Equivalents (2017 - 2025)

Cue Biopharma has disclosed Cash & Equivalents across 9 years of filings, most recently posting $26.6 million for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $26.6 million, up 18.44% year-over-year; the trailing twelve-month figure through Dec 2025 was $26.6 million (up 18.44% YoY), and the FY2025 annual result was $26.6 million, up 18.44% from the prior year.
• Cash & Equivalents came in at $26.6 million for Q4 2025 at Cue Biopharma, up from $11.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $73.9 million in Q2 2021 to a low of $11.2 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $50.1 million (2022), against an average of $45.0 million.
• Across the five-year window, Cash & Equivalents jumped 212.64% in 2021 and sank 67.98% in 2025, its largest moves.
• Cue Biopharma's Cash & Equivalents stood at $52.2 million in 2021, then fell by 1.14% to $51.6 million in 2022, then retreated by 6.01% to $48.5 million in 2023, then tumbled by 53.71% to $22.5 million in 2024, then advanced by 18.44% to $26.6 million in 2025.
• The last three Cash & Equivalents figures came in at $26.6 million (Q4 2025), $11.2 million (Q3 2025), and $27.5 million (Q2 2025), per Business Quant data.